Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom

The article compares Abbott Laboratories and Dexcom as the two leading CGM players, highlighting Abbott's larger installed base, broader diversification, and Dividend King status versus Dexcom's faster growth and higher risk. Abbott's FreeStyle Libre franchise has surpassed 5 million patients and become the best-selling medical device ever by dollar sales, while Abbott also points to growth from Exact Sciences' $21 billion acquisition. The piece is largely valuation- and strategy-oriented rather than news about a new financial result, so near-term market impact is likely limited.

Analysis

The market is implicitly treating CGM as a winner-take-most category, but the more important question is whether it remains a high-growth category at all once GLP-1 adoption fully feeds through. If GLP-1s reduce the marginal need for frequent glucose monitoring in a meaningful slice of type 2 patients, the first-order hit is to device growth, but the second-order winner is likely the lower-cost, broader-distribution platform with the best channel leverage and reimbursement resilience. That favors ABT on downside protection, while DXCM’s equity remains the cleaner expression of a still-intact CGM TAM expansion thesis.

The key underappreciated risk is not near-term unit share but margin durability. As over-the-counter and lower-feature products proliferate, pricing power can compress faster than installed-base growth expands, especially if insurers and consumers anchor on entry-level SKUs. In that setup, DXCM’s smaller scale is a double-edged sword: faster top-line beta in a good tape, but a much sharper multiple de-rating if growth decelerates for even 2-3 quarters.

A second-order beneficiary outside the headline pair is EXAS, because any broader normalization in non-CGM chronic-care spending shifts attention toward preventive diagnostics and screening categories with clearer utilization gaps. ABT’s diversification also creates a hidden call option: if one subsegment stalls, capital can be redirected toward faster-growing franchises without forcing a selloff in the core story. That makes ABT more of a compounder-with-put-protection than a pure growth vehicle.

Consensus still looks too binary: investors are framing this as either CGM dominates or GLP-1 kills the thesis. The more likely outcome is slower-but-longer adoption, where the category grows, but the winners are determined by distribution, reimbursement, and price elasticity rather than pure product performance. That argues for owning ABT as the lower-volatility expression and only owning DXCM if you have conviction that growth can reaccelerate within the next 4-6 quarters.

Key Decisions for Investors

• Long ABT / short DXCM as a 6-12 month relative-value pair: prefer the more diversified balance sheet and dividend support while fading the higher-multiple name if CGM growth slows or pricing compresses.
• Initiate a small tactical long in DXCM only on a 15-20% pullback or after a clean reacceleration print; target a 2:1 upside/downside setup, but size below core due to GLP-1 and pricing-risk convexity.
• Use ABT as the defensive healthcare accumulator for the next 2-4 quarters; dividend plus franchise diversification should dampen drawdowns if CGM sentiment rolls over.
• Buy a modest EXAS position on weakness as a second-order beneficiary of healthcare budget rotation and underpenetrated screening demand; horizon 6-18 months.
• If holding DXCM into earnings, hedge with short-dated put spreads into the print; the main risk is not a catastrophic miss but multiple compression on any guidance that implies slower adoption.